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Inconsiderate CPD decision  
To the Editor: I was surprised and indeed indignant to read in 
the January SAMJ that as from the end of February, manually 
completed CPD questionnaires would not be accepted.
Is this a not-so-subtle ploy to ensure that older practitioners 
cannot meet the CPD requirements and are therefore 
deregistered? Many older doctors are not computer literate 
and this decision means that the simplest way of acquiring 
CPD points is no longer an option for them. I thought your 
comment in the Journal – the equivalent of ‘hard cheese ’– was 
inappropriate.
Apart from lack of expertise, the cost of sitting on line, 
on a dial-up line, while completing the questionnaire is 
prohibitive – all in all a bad and inconsiderate decision from 
SAMJ management. To quote you know who – ‘It is totally 
unacceptable’.
Joce Kane-Berman
Gardens, Cape Town
pritch@iafrica.com
The CPD paper trail is prohibitively expensive, and the Board has 
determined that the publishing division must contain costs. I am 
sorry that my comments came across as ‘hard cheese’ – that was not 
intended. We had anticipated difficulties with the new process and 
have not been disappointed. Emily Nel at the SAMA Western Cape 
Branch has indicated her willingness to enter the questionnaires on 
behalf of members unable to do so. Perhaps other branches could also 
oblige for their members? – J P van Niekerk (Ed.)
Discovering familial hypercholesterol-
aemia
To the Editor: We are concerned that patients with monogenic 
dyslipidaemias may be denied effective treatment for their 
high-risk condition by some questionnaires used by the 
medical schemes industry.
Familial hypercholesterolaemia (FH) is highly prevalent 
in South Africa owing to the presence of founder effects in 
several populations.1 If it is left untreated, markedly premature 
atherosclerosis is the usual outcome. Algorithms that estimate 
the 10-year risk of cardiovascular events (e.g. Framingham 
study-based charts) usually grossly underestimate actual risk 
in FH. Guidelines therefore recommend that patients with FH 
should not be risk-scored.2 Chronic medication application 
forms therefore need to make provision for the diagnosis of FH 
in addition to collecting data for risk estimation. 
The definitive diagnosis of FH can be difficult. Not all 
patients display the characteristic tendon xanthomata, and 
the family history is not always available and does not always 
reveal premature heart disease. Genetic tests are not the 
answer as there are more than 1 000 described mutations in 
the low-density lipoprotein (LDL)-receptor gene, and this is 
not the only gene associated with the phenotype. Medication 
application forms attempt to capture these complexities in one 
or two lines. This is often not done effectively, as in the current 
Discovery Health form.3 
Doctors are asked to indicate whether there are signs 
of familial hyperlipidaemia. The options presented are 
xanthelasma, cerebrotendinous xanthomatosis and arcus 
cornealis. None of these aids in the diagnosis of FH. 
Xanthelasma are a poor sign of raised cholesterol, and 
arcus cornealis is similarly nonspecific. Cerebrotendinous 
xanthomatosis (CTX) is a very rare autosomal recessive 
abnormality of bile acid metabolism that results in cataracts, 
neurological dysfunction and tendon xanthomata.4 CTX and 
FH share tendon xanthomata as a cardinal physical sign but are 
otherwise very different conditions.
This leaves plasma lipids and a limited family history table 
as data on which to base funding decisions. These decisions 
risk being inappropriate with potentially severe consequences, 
and reversing them is often time-consuming. Other medical 
funders require FH to be diagnosed by endocrinologists. FH 
is a common disorder that should be diagnosed by general 
practitioners with backup, as needed, from a specialist or 
a lipid clinic.5 The diagnosis of FH should be entrusted to 
medical practitioners and not medical schemes. 
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